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Oxygen deprivation and infection are major causes of perinatal brain injury leading to 
cerebral palsy and other neurological disabilities. The identification of novel key factors 
mediating white and gray matter damage are crucial to allow better understanding of 
the specific contribution of different cell types to the injury processes and pathways 
for clinical intervention. Recent studies in the Rice–Vannucci mouse model of neonatal 
hypoxic ischemia (HI) have highlighted novel roles for calcium-regulated peptidylargi-
nine deiminases (PADs) and demonstrated neuroprotective effects of pharmacological 
PAD inhibition following HI and synergistic infection mimicked by lipopolysaccharide 
stimulation.
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inTRODUCTiOn
Hypoxia and synergistic infection are major causes of perinatal brain injury (1–3), contributing 
to neurological disabilities affecting 1–8 cases per 1000 live births in the Western world and up to 
26 per 1000 live births in underdeveloped countries (4, 5). In the acute phase of hypoxic–ischemic 
encephalopathy (HIE), cerebral blood flow is decreased, resulting in reduced oxygen and glucose 
delivery to the brain and anaerobic metabolism. Subsequent adenosine triphosphate (ATP) deple-
tion leads to intracellular accumulation of sodium, water, and calcium due to reduced transcellular 
transport (6, 7). The cell releases excitatory glutamate upon membrane depolarization, allowing 
calcium to flow into the cell via N-methyl-d-aspartate (NMDA)-gated channels. The resulting 
peroxidation of free fatty acids by oxygen free radicals leads to more cellular damage. The culmi-
nation of energy failure, acidosis, glutamate release, lipid peroxidation, and toxic effects of nitric 
oxide (NO) leads to cell death via necrosis and apoptosis (7–9). The re-oxygenation stage following 
a neonatal hypoxic ischemia (HI) insult is followed by an intermediate “grace period” with little 
overt metabolic, nuclear magnetic resonance (NMR), or histological abnormalities, and only then 
by secondary energy failure, inflammation, apoptotic, necrotic and/or autophagic cell death, and 
axonal degeneration (10–13). During this intermediate phase, changes in cellular transcription, 
de novo protein synthesis, and posttranslational modifications all play pivotal roles (14–16). The 
tertiary phase of HIE during the months after the acute insult involves late cell death, remodeling of 
the injured brain, and astrogliosis (Figure 1).
Experimental studies in HIE animal models have shown roles for epigenetic mechanisms (18, 
19), pH changes (20–22), and the tumor necrosis factor (TNF) gene cluster of cytokines in a com-
bined inflammatory and HI brain insult (23). Clinical studies have shown protective therapeutic 
FiGURe 1 | Phases of injury post-Hie. Phase I at 0–6 h post-insult includes vasculature changes and primary energy failure. This results in loss of autoregulation 
and severe lowering of the systemic arterial blood pressure. This causes decrease in oxygen, depletion of ATP, increased excitotoxicity, raised intracellular calcium, 
oxidative stress (ROS), and mitochondrial dysfunction. Phase II at 6–48 h post-insult and secondary energy failure lead to continued excitotoxicity, mitochondrial 
dysfunction, and oxidative stress; reduced phosphate levels. Phase III post 48 h shows injury to microglia, neurons, and astrocytes and also leads to continuous 
release of cytokines and other detrimental factors causing chronic inflammation, which in turn lead to epigenetic changes, as well as impairment of synaptogenesis, 
axonal growth, and neurogenesis. The tertiary phase continues months after injury involving late cell death, brain remodeling, and astrogliosis [based on Ref. (7, 17)].
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effects of hypothermia (24), which remains the standard care 
for HIE. Recent translational studies demonstrated significantly 
enhanced neuroprotection following co-therapy of hypothermia 
with xenon (25) or melatonin (26). Therefore, novel targets for 
synergistic therapies to enhance post-insult neuroprotection are 
of considerable interest.
PePTiDYLARGinine DeiMinASeS
The peptidylarginine deiminase (PAD) enzymes are a family 
of five calcium-dependent mammalian isozymes (PAD1, 2, 
3, 4/5, and 6), located within a 355-kb gene cluster on human 
chromosome 1p36.13 (27–29) and mouse chromosome 4E1 
with intron and exon boundaries well conserved throughout the 
evolution (27, 30). Each PAD isozyme has a unique tissue dis-
tribution pattern and substrate preferences (28, 31). PADs cause 
posttranslational protein deimination by modifying positively 
charged protein arginine residues into hydrophilic but uncharged 
citrullines, producing a loss of one positive charge per conversion 
and release of ammonia (30). The incidental disruption of ionic 
and hydrogen bonds within the substrate proteins affects protein 
structure, function, and protein–protein interactions (Figure 2). 
Main target proteins identified include nuclear histones (32), 
cytoskeletal, and structural proteins, such as components of the 
myelin sheath, intermediate filaments and associated adaptor 
proteins, extracellular components including fibrin and fibronec-
tin (19, 33), and the chemokines (34–36). Intrinsically disordered 
proteins and β-turns are particularly prone to deimination (33). 
Deimination also has autoregulatory activity on PAD enzymes 
themselves and also upstream cytokines and chemokines, such 
as TNFα, C–X–C motif chemokine (CXCL) 8, and CXCL10 
(37, 38). PADs are involved in physiological processes during 
development – including nerve growth and differentiation, gene 
regulation, regulation of pluripotency, and cell death (39–43). 
PAD dysregulation is associated with various inflammatory and 
degenerative diseases (30, 33, 34). PADs are also implicated in 
cancer (44–46), including through regulation of microvesicular 
(MV) release (47), which also is related to cerebral hypoxia 
induced by acute ischemic stroke (48, 49). PAD2 is considered the 
main central nervous system (CNS) isozyme (50), but PAD3 and 
PAD4 are also detected in neuronal tissue (19, 51, 52). PAD4 is the 
only isozyme with a designated nuclear translocation site, but the 
nuclear translocation of PAD2 and PAD3 has also been reported 
(19, 43, 44, 47). A novel role for PADs in acute CNS damage, 
and significant neuroprotective measures using pharmacological 
pan-PAD inhibition (Cl-amidine), was first described in a chick 
model of spinal cord injury (19). This neuroprotective effect was 
shown to be translatable to the Rice–Vannucci neonatal HI mouse 
FiGURe 2 | Mechanisms of peptidylarginine deiminases (PADs) in Hi and synergistic infection. Upon HIE, Ca2+ entry is facilitated via reversal of the Na+/
Ca2+ exchanger due to over activation of the Na+/H+ exchanger (NHE). Ca2+ entry can also be facilitated due to membranolytic pathways including the complement 
membrane attack complex (MAC) and perforin. Increased cytosolic Ca2+ triggers the neurotoxic cascade, which includes activation of the Ca2+-dependent PAD 
enzymes. Upon increased intracellular Ca2+, resting PADs are activated and catalyze the conversion of arginines into citrullines in target proteins. Protein deimination 
causes conformational changes and protein misfolding, affecting protein function and protein–protein interaction. Actin and cytoskeletal rearrangement is affected 
causing changes in cell motility, microvesicular (MV) release, autophagy, and phagoptosis. Deiminated neo-epitopes result in damage-associated molecular patterns 
(DAMPs) and contribute to inflammatory processes, such as microglial activation and downstream cascades. Inflammation causes upregulation of TNFα, which also 
is induced upon infection as mimicked by LPS stimulation in the HI/LPS synergy model. Raised TNFα levels cause translocation of PADs into the nucleus where they 
deiminate histones and affect gene regulation and epigenetics. Histone deimination also leads to extracellular trap formation (NETosis), which forms part of the 
microbial defense but can also cause the generation of neo-epitopes, leading to auto-inflammatory responses. Zinc is hypothesized to be a regulator of PADs, and 
as zinc levels are reduced in sites of infection, this regulatory role is lost, leading to increased protein deimination during infection. Individual variations of the neonatal 
microbiome may add to the complexity of the interplay of microbial defenses via NETosis and impact microglial activation and other mechanisms that remain to be 
elucidated. PAD inhibition with the pan-PAD inhibitior Cl-amidine has been successful in neuroprotection in the Rice–Vannucci mouse model of HI and HI/LPS 
synergy model, significantly reducing microglial activation, neuronal loss, and cell death. Refined inhibitors of PAD activation thus pose promising combinatory 
treatment options in synergy with current hypothermia measures.
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model, resulting in significant protection of neuronal tissue and 
reduced microglial activation and cell death (53).
PADs in ePiGeneTiCS
Epigenetic roles for PADs in gene regulation are supported in 
both HIE and HIE/lipopolysaccharide (LPS) synergy models 
where histone deimination, caused by PADs translocated to the 
nucleus, was abolished upon PAD inhibition. This paralleled the 
significant reduction observed in brain tissue loss, particularly 
in the cortex and hippocampus, which were the main areas 
affected (53). The LPS/HI model of infectious/ischemic form of 
brain damage is known to be strongly dependent on TNFα and 
related family of cytokines as global gene deletion of the whole 
TNF cluster of cytokines completely abolishes the synergistic, 
damage-enhancing effect of LPS on HI insult (23). In a transgenic 
multiple sclerosis murine model, exposure to elevated levels of 
TNFα-elicited nuclear translocation of PAD4 (54). In the same 
vein, PAD activity induced by HI insult and LPS stimulation 
increased neuronal damage following HI insult with beneficial 
effect of PAD inhibition. This indicates that LPS-induced upregu-
lation of macrophage TNFα and related cytokines may act as 
upstream signals to PADs and histone deimination in HIE as well 
as in other forms of brain damage [(52); Figure 2].
PADs in PHAGOPTOSiS
Microglia, the professional brain phagocytes, are strongly acti-
vated in HIE and can partly reduce inflammation by phagocytosis 
of dead/dying neurons and neuronal debris (9, 55–57). Microglia 
have also been shown to phagocytose live neurons, neutrophils, 
neural progenitors, and glioma cells causing death of the engulfed 
cell (58–62). Some phosphatidylserine (PS)-exposing neurons 
may be able to reverse their “eat-me” signals but still be phago-
cytosed via phagoptosis (62), which may dominate in conditions 
in which toll-like receptors (TLRs) are activated, as through LPS 
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stimulation (58, 59). The roles of TLRs differ in the immature and 
adult brain following brain damage (63). Microglial activation 
can cause neurotoxicity by various other mechanisms, including 
NO generation by inducible NO synthase (iNOS), which inhibits 
neuronal mitochondria (64), or oxidant formation by phagocyte 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
causing direct neurotoxicity (62, 65). In areas of ischemia and 
hypoxia, phagocytosis of dead or dying neurons may decrease 
inflammation by clearing harmful cellular components. Following 
mild ischemia, blocking phagocytosis could be beneficial by 
preventing the phagocytosis of stressed, but viable, neurons (59). 
Viable neurons in the post-ischemic brain are labeled by annexin 
V, indicating PS exposure that peaks at 3  days after transient 
ischemia and reverses thereafter (66), making these PS-exposed 
neurons targets for phagocytosis (59). The presence of phospho-
lipids has been shown to reduce the calcium dependence of PAD2 
by almost twofold in  vitro (67), indicating that PAD activation 
may be facilitated in the presence of PS in vivo. In HIE, reduced 
microglial activation was observed 48 h post-insult in PAD inhib-
itor-treated animals in all brain regions and could be crucial for 
the protection of PS-exposed neurons against phagoptosis. This 
may be reflected in the significant reduction observed in neuronal 
loss in the PAD inhibitor-treated animals (53). Actin polymeriza-
tion, facilitated by deimination and required for this mechanism, 
may be inhibited with PAD blockers as recently described in the 
regulation of cellular MV release (47). Actin, vimentin, and other 
cytoskeletal proteins were identified to be deiminated in acute 
CNS damage (19), while PAD3 inhibition has been shown to cause 
cytoskeleton disassembly in human neural stem cells as well as 
apoptosis-inducing factor (AIF) translocation to the nucleus (43). 
AIF has been shown to be a major contributor to neuronal loss 
induced by neonatal cerebral hypoxia-ischemia (68).
PADs in AUTOPHAGY – DeiMinATeD 
neO-ePiTOPeS
Autophagy is a cellular death mechanism recently implicated in 
HIE as a potential therapeutic target (69). This lysosomal pathway 
for intracellular degradation of macromolecules and organelles 
is important in the maintenance of cellular survival and homeo-
stasis (70). Results are conflicting as pharmacological inhibition 
of autophagy was reported as neuroprotective (71), while studies 
inducing autophagy immediately after injury indicated it to be 
an endogenous neuroprotective mechanism (72). Recently, PAD4 
was implicated in the induction of autophagy in hepatocellular 
carcinoma (73). Deiminated peptides were also shown to be 
processed in autophagy vesicles of antigen-presenting cells, indi-
cating a linkage between autophagy and autoreactivity through 
the generation of deiminated neo-epitopes (74, 75), which in HIE 
could contribute to neuroinflammatory responses.
PAD ACTivATiOn viA MeMBRAnOLYTiC 
PATHwAYS
Perforin and complement mediate membranolytic pathways of 
the cellular and humoral immune response and use a common 
“membrane attack complex component/perforin” (MACPF) 
domain to form pores in membranes to exert their potent 
anti-pathogen activity (76). Roles for both pathways have been 
described in the generation of hypercitrullinated proteins in rheu-
matoid arthritis (RA) (77). In a rodent study of HIE, the admin-
istration of complement C9 appeared detrimental (78) – which 
makes it tempting to speculate that hypercitrullinated proteins 
may be generated in HI in a similar fashion and contribute to 
microglial activation and neuroinflammatory damage.
Perforin oligomerizes in a Ca2+-dependent manner to form 
pores on target cells, triggering influx of calcium (79). In RA, 
this mechanism induced hypercitrullination in neutrophils, 
which express the PAD2, PAD3, and PAD4 isozymes, with each 
isozyme generating a distinct pattern of protein deimination (77). 
Again, it is tempting to speculate whether perforin contributes to 
neuroinflammatory responses in HIE.
ZinC – A ReGULATOR OF PAD 
ACTivATiOn?
Zinc is hypothesized to be an upregulatory modulator of 
calcium-dependent activation of posttranslationally acting PADs 
in autoimmune diseases (80). Zinc has previously been shown 
to inhibit the calcium-induced activation of PAD4 (81), and one 
can speculate that it may have a regulatory role for PADs in HIE. 
Putative links between zinc deficiency and HIE has been touched 
upon (82) in the context of effects of oxidative stress in child-
hood and neonatal disorders. The role of zinc may be particularly 
interesting with respect to HIE and synergistic infections as the 
zinc concentration is thought to be downregulated upon infec-
tion (80). This may cause downstream activation of the PAD 
cascade and further contributes to neuroinflammatory responses 
in HIE (Figure 2). Whether supplementing neonates with zinc as 
a preventive measure is open to debate.
PADs in neUTROPHiL eXTRACeLLULAR 
TRAP FORMATiOn (neTosis) – inTeRPLAY 
wiTH THe MiCROBiOMe
Recent studies have highlighted increasingly diverse roles for 
histone deimination including in NETosis, which forms part 
of the innate immune response in microbial defense and is 
implicated in autoimmunity (83). NETosis has recently received 
attention in neonatal infections (84) as neonatal neutrophils 
from umbilical cord were shown to differ significantly from 
adult controls in proteomic analysis and function including 
delayed NETosis (85). NETosis is dependent on the PAD4 
isozyme (86, 87), which upon neutrophil activation, catalyzes 
arginine citrullination in three of the four core histones (88, 
89). PAD4-null mice have been shown to fail to produce NETs, 
which coincides with lack of histone3 hypercitrullination (90). 
NETs are composed of DNA strands associated with antibacte-
rial granular proteins, including deiminated histones, neutro-
phil elastase, myeloperoxidase, lactoferrin, and defensins (91). 
During inflammation, NETs can alert the immune system to 
danger by activating DNA receptors, such as TLR-9, helping in 
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the recruitment of immune cells. TLR-9 activation via NETs in 
dendritic cells produces interferons, which can in turn initiate 
autoimmune responses (92, 93). Also, proteolytic and oxidative 
processing of proteins during NETosis can generate neoantigens 
(91), and NETosis has indeed been connected to several autoim-
mune diseases (92–97).
Neonatal neutrophils can form robust cellular aggregates 
and are able to release NETs in response to fungal hyphae 
when presented with extracellular matrix (84). In preeclampsia 
placentas, NETs have been shown to be in close contact with 
the syncytiotrophoblast, putatively obstructing the intervillous 
space, reducing blood flow, and leading to hypoxia in the fetus 
(98). NETosis can also be induced by activated endothelial cells 
and cause damage of the endothelium leading to more severe 
preeclampsia (99).
In the murine HIE/infection synergy model, LPS stimulation 
prior to neonatal HI insult may activate NETosis, which can result 
in further damage of surrounding tissue – emphasizing that this 
innate defense mechanism may be a double-edged sword when 
toxicity is directed against own tissues (53). It is interesting to 
note that PAD inhibitor effectively reduced histone deimination, 
which coincided with significantly reduced neuronal damage 
and cell death (53). As NET formation has been shown to require 
functional tubulin and actin filaments (100) and PAD blocker 
inhibits actin and tubulin deimination (19, 47), this may affect 
the ability of NET formation.
The capability of premature and healthy term infant cord neu-
trophils to form NETs is based on material from cords donated 
after cesarean section (84, 86). Labor deliveries are reported 
to increase the surface expression of TLRs on monocytes, and 
interleukin 8-induced neutrophil chemotaxis has been shown 
to be enhanced due to the stress of birth (101). As the effect of 
the microbiome in health and disease is gaining ever increasing 
attention, differences in the maternal and neonatal microbiome 
are emerging as crucial in response to infection, development, 
and neurological developmental disorders (102–104). It is 
tempting to speculate how individual differences in the neonatal 
microbiome may affect the capability of dealing with infections 
via mechanisms, such as NETosis – also in the wider context of 
cesarean sections versus vaginal delivery and breastfeeding – both 
of which influence the microbial colonization of the gut and the 
composition of the microflora (105, 106). This is particularly 
interesting with respect to emerging evidence of the importance 
of the neonatal gut–brain axis (107), a link between microglial 
maturation and the microbiome (108), sexual dimorphism in 
microglial numbers and response to HIE (109), and the connec-
tion between the maternal microbiome and pregnancy outcomes, 
including preterm births (110). Future studies comparing the 
effect of cesarean section versus labor delivery on the neonatal 
response to fungal infections and other pathogens will provide 
better understanding of the role of NETosis and PADs in neonatal 
HIE and synergistic infections.
pH CHAnGeS AnD PAD ACTiviTY
Brain intracellular pH (pHi) is implicated in HIE (20–22). 
The Na+/H+ exchanger, which regulates pHi and cell volume, 
is over-activated during HIE, resulting in Ca2+ entry via 
reversal of the Na+/Ca2+ exchanger. Increased cytosolic Ca2+ 
triggers the neurotoxic cascade, which includes activation of 
the Ca2+-dependent PAD enzymes and downstream protein 
deimination (Figure  2). Activation of the Na+/H+ exchanger 
also leads to rapid normalization of pHi and to an alkaline 
shift. Brain pHi changes are closely involved in the control of 
cell death after injury as alkalosis enhances excitability, while a 
mild acidosis has the opposite effect (21). The degree of brain 
alkalosis in 78 babies with neonatal encephalopathy was related 
to the severity of brain injury (21). The effect of pH on PAD-
catalyzed reaction and its kinetics has been studied to some 
extent (81). PAD4 has pKa values of ~6.2 and ~7.9, the pH 
optimum being pH 7.6, while calcium dependence of PAD4 
is essentially pH-independent over the range of pH 6.0–8.5 
(81). The PAD activation pathway should thus be stable over a 
relatively wide pH range.
HYPOTHeRMiA AnD PAD inHiBiTiOn – A 
SYneRGiSTiC TReATMenT OPTiOn
Cooling brain or whole body to 33°C (moderate hypothermia) is 
currently the only strategy with a clearly demonstrated clinical 
benefit in babies with HIE. Therapeutic hypothermia promotes 
neuroprotection by several mechanisms including a decrease in 
intracellular calcium influx, which may improve serum Ca2+ lev-
els and homeostasis (111–114). Excessive Ca2+ influx during and 
after a significant HI insult promotes depolarization of the mito-
chondria and abnormal excitatory receptor activity promoting 
further Ca2+ entry into the cells (113). Post-insult hypothermia 
suppresses this intrinsic pathway (114) and should also affect 
the Ca2+-regulated PAD activation pathway as calcium binding 
to PAD4 promotes the bioactive conformation, increasing PAD4 
activity by 10,000-fold (115). The effects of cooling on calcium 
levels was investigated in a piglet model where plasma calcium 
increased to levels compared with normothermic animals within 
3 h of hypothermia and could thus aid Ca2+ homeostasis in HIE 
(116). As several injury-associated signals, e.g., phosphorylated 
extracellular signal-regulated kinases (ERK), are increased fol-
lowing hypothermic intervention (117), combined therapies are 
desirable for increased neuroprotective effects. Hypothermia 
has been combined with adjunct therapy including xenon, 
erythropoietin, melatonin, and stem cells for substantial neuro-
protection (118–125).
The success of reducing brain injury responses with phar-
macological PAD inhibition in murine mouse models of HIE 
is promising as the treatment proved translatable between both 
animal and neuronal injury models. The effects observed on 
changes in histone deimination suggest a role for epigenetic regu-
lation in response to CNS injury, while changes in deimination of 
cytoskeletal components could affect apoptosis, cell motility, and 
the ability of injured neurons to regrow axons (19, 43, 53). While 
the pan-PAD inhibitor Cl-amidine (126) still remains the most 
used experimental inhibitor to date, the therapeutic potential and 
generation of selective PAD inhibitors is receiving ever increasing 
attention (52, 127–131).
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COnCLUSiOn
A novel role for calcium-dependent PAD is highlighted in neural 
impairment in neonatal HIE, emphasizing their role as promising 
new candidates for drug-directed intervention in neurotrauma. 
During hypoxic ischemic insult, PADs are activated due to 
calcium dysregulation and putative upregulatory changes in 
zinc balance, which is decreased upon synergistic infection. 
Deiminated proteins are irreversibly modified due to changes of 
protein-bound arginines into citrullines, leading to protein mis-
folding and changes in protein function. In the case of synergistic 
infection, TNFα is upregulated and causes nuclear translocation 
of PAD enzymes, resulting in histone deimination and down-
stream changes in gene regulation. Mechanisms of PADs in HIE 
also touch upon the interplay of the microbiome, cesarean versus 
vaginal deliveries, and how neutrophil and microglial responses 
to pathogens could be affected. Isozyme-specific PAD inhibition 
through refined pharmacological intervention poses a promising 
combinatory treatment option in synergy with current head-
cooling approaches.
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